Rochester, NY 7/15/2009 3:47:21 AM
IMMU - Immunodedics Updates on Results of Patients with Non-Hodgkin's Lymphona
Immunomedics, Inc.
Immunomedics, Inc., IMMU
WhisperFromWallStreet.com offers daily stock alerts to subscribers. Sign up for our free alerts newsletter.
Immunomedics, Inc. announced that epratuzumab labeled with the potent radioisotope, yttrium-90 (Y-90), when given in small fractionated doses to patients with non-Hodgkin's lymphoma (NHL), achieved high rates of durable responses at total Y-90 doses exceeding the 32-mCi limit approved for a single dose of ibritumomab tiuxetan. The goal of the study is to determine the safety, optimal dosing and preliminary efficacy of Y-90-labeled epratuzumab (yttrium-90 epratuzumab tetraxetan) for NHL. 64 adult patients who had failed one or more therapies, including rituximab, had been enrolled to receive 2 or 3 weekly infusions of Y-90 labeled epratuzumab.
About WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Sign up for our FREE alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
